Pharming Group N v (PHAR) |
|
Price: $11.4888
$0.57
5.209%
|
Day's High:
| $11.4888
| Week Perf:
| -1.38 %
|
Day's Low: |
$ 11.34 |
30 Day Perf: |
-12.96 % |
Volume (M): |
3 |
52 Wk High: |
$ 17.81 |
Volume (M$): |
$ 30 |
52 Wk Avg: |
$11.89 |
Open: |
$11.42 |
52 Wk Low: |
$9.70 |
|
|
Market Capitalization (Millions $) |
8,268 |
Shares
Outstanding (Millions) |
720 |
Employees |
180 |
Revenues (TTM) (Millions $) |
206 |
Net Income (TTM) (Millions $) |
14 |
Cash Flow (TTM) (Millions $) |
192 |
Capital Exp. (TTM) (Millions $) |
1 |
Pharming Group N V
Pharming Group N.V. is a Dutch biopharmaceutical company specializing in the development of innovative treatments for rare diseases. The company has its headquarter in Leiden, the Netherlands and operates globally.
Pharming is primarily focused on developing products for the treatment of hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent episodes of swelling and inflammation. The company's most significant product is RUCONEST, a recombinant human C1 esterase inhibitor used to treat acute attacks of HAE. RUCONEST is approved for use in Europe and the United States and has been used by thousands of patients worldwide.
Pharming is also developing new products for the treatment of other rare diseases, including Pompe disease, Fabry disease, and phenylketonuria. The company's pipeline also includes products for the treatment of various types of cancer, including Natural Killer T-cell lymphoma and acute myeloid leukemia.
The company has received numerous awards and recognitions for its innovations in the biopharmaceutical industry. Pharming was awarded the Best Performing Biotech in Europe in 2019 and was named one of the top ten most innovative companies in the Netherlands by the Dutch Chamber of Commerce.
In addition to its focus on research and development, Pharming is active in promoting patient awareness and advocacy. The company works closely with patient organizations to improve patient access to treatments and supports various patient education initiatives.
Pharming has a strong financial position, with steady growth in revenue and market capitalization over the past few years. The company is publicly traded on multiple stock exchanges, including Euronext Amsterdam, NASDAQ, and the Swiss SIX Exchange.
Overall, Pharming Group N.V. is a highly respected and innovative biopharmaceutical company that is dedicated to improving the lives of patients with rare diseases through the development of effective and safe treatments.
Company Address: Darwinweg 24 Leiden 2333
Company Phone Number: 5247 400 Stock Exchange / Ticker: NASDAQ PHAR
PHAR is expected to report next financial results on April 04, 2024. |
|
|
|
|
|
|
Stock Performances by Major Competitors |
|
|
Leap Therapeutics Inc
Leap Therapeutics Inc, a major pharmaceutical preparations company, recently reported its financial results for the October to December 31, 2023 reporting season. While shareholders had not anticipated any significant changes, they were disappointed to observe an operating deficit of $14.82 million during this period. This represents a decline compared to the fourth quarter of 2022, when the operating deficit stood at $13.943 million. Furthermore, the company recorded a shortfall of $12.465 million, a significant increase from the previous year's $12.102 million deficit. These figures highlight the challenging environment faced by Leap Therapeutics Inc during the specified timeframe.
|
Xbiotech Inc
Xbiotech Inc., a leading biotechnology company, recently released its financial results for the fiscal period ending December 31, 2023. The company reported a loss of $0.15 per share, compared to $0.10 per share the previous year, while Income per Share improved from $0.24 to $0.00 per share from the previous quarter. Despite the losses, the company remains optimistic about its future growth prospects. One interesting fact from the financial report is that Xbiotech Inc. realized a net shortfall of $4.635 million, which is higher than the $3.203 million reported a year ago. Additionally, the company also noted a shortfall of $24.56 million for the financial period 2023. Despite these challenges, the company is committed to innovation and advancing the frontiers of medical science.
|
Acurx Pharmaceuticals Inc
Acurx Pharmaceuticals Inc, a Major Pharmaceutical Preparations company, has seen a significant drop in its stock price over the past year. The stock has dropped by -21.13% compared to a year ago, and by -35.48% in the past 90 days. Currently trading on the NASDAQ, the stock is -7.5% below its 52-week average. The company recently reported its financial results for the period ending December 31, 2023, and shareholders have expressed concerns about the top-line performance. The operating shortfall for Acurx Pharmaceuticals Inc was at $-5.11459 million, which represents a contraction from $-3.260511 million in the fourth quarter of 2022. Analysts are closely watching to see if the company can improve its revenue numbers in the coming quarters.
|
Soligenix Inc
As a financial journalist for the , I have been closely following the recent financial results of Major Pharmaceutical Preparations company, Soligenix Inc. The company's performance in the October to December 31, 2023 period has shown some improvement compared to the previous year. In the fourth quarter of 2023, Soligenix Inc reported a net shortfall of $-1.820 million, a significant improvement from the $-11.901 million deficit in the same quarter a year ago. The company also managed to reduce its shortfall per share to $-0.17 from $-4.14 in the previous year, indicating progress in their financial performance. Despite the positive changes, Soligenix Inc's revenue deteriorated by -11.55% from $0.95 million in the previous year. However, in the recent quarter, revenue surged by 87.682% from $0.13 million in the prior quarter, showing a promising trend for the company's future financial performance.
|
Eterna Therapeutics Inc
In the fourth quarter of 2023, Eterna Therapeutics Inc, a major pharmaceutical preparations company, disclosed revenue of $0.017 million, marking a slight increase from the previous year. However, the company also reported a net deficit of $-6.153 million for the same quarter, which was larger than the deficit of $-4.490 million in the previous year. This increase in deficit is concerning to analysts, especially as the level of accounts receivable has declined to $0.4 million, indicating a potential slowdown in demand for the company's products. Furthermore, Eterna Therapeutics Inc indicated a net deficit of $-21.67 million for the fiscal year 2023, along with revenue of $0.07 million. Despite these challenges, the company has managed to decrease its deficit per share to $-4.08 from $-8.06 in the preceding fiscal year, showing some improvement in its financial performance.
|
Per Share |
Current |
Earnings (TTM) |
0.02 $ |
Revenues (TTM) |
0.29 $
|
Cash Flow (TTM) |
0.27 $ |
Cash |
0.29 $
|
Book Value |
0.28 $
|
Dividend (TTM) |
0 $ |
|
Per Share |
|
Earnings (TTM) |
0.02 $
|
Revenues (TTM) |
0.29 $ |
Cash Flow (TTM) |
0.27 $ |
Cash |
0.29 $
|
Book Value |
0.28 $ |
Dividend (TTM) |
0 $ |
|
|
|
|